Literature DB >> 10660497

Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.

L J Piddock1, K J Williams, V Ricci.   

Abstract

The characteristics of the accumulation of 2 mg/L [(14)C]rifampicin by wild-type strains of Mycobacterium aurum (A(+)), Mycobacterium smegmatis (mc(2)155) and Mycobacterium tuberculosis (H37Rv) were determined. After 10 min exposure M. aurum had accumulated 220 ng rifampicin/mg cells, M. smegmatis had accumulated 120 ng rifampicin/mg cells and M. tuberculosis had accumulated 154 ng rifampicin/mg cells. A steady-state concentration (SSC) of rifampicin was accumulated rapidly by M. aurum and M. tuberculosis within minutes of drug exposure, unlike M. smegmatis, which accumulated rifampicin more slowly. With an increase in the concentration of rifampicin from 0.12 mg/L to 2 mg/L there was an increase in the concentration of rifampicin accumulated by M. tuberculosis, with no detectable loss of viability over the 20 min of the accumulation experiment. With an increase in temperature there was also an increase in the concentration of rifampicin accumulated by M. tuberculosis; between 15 and 30 degrees C the increase was linear. For all three species sub-inhibitory concentrations of ethambutol increased the concentration of rifampicin accumulated. However, both growth and accumulation of rifampicin were lower in the presence of 0.05% Tween 80. Accumulation of rifampicin by M. smegmatis was unaffected by the presence of the proton motive force inhibitor, 2,4-dinitrophenol (1 mM), whether added before or after the addition of rifampicin to the mycobacterial culture. For all three species, the Gram-positive bacterial efflux inhibitor reserpine (20 mg/L) slightly increased the SSC of rifampicin, but the increase was not statistically significant. Addition of glucose to energize a putative efflux pump had little effect on the accumulation of rifampicin in the presence or absence of reserpine for M. tuberculosis; however, for M. aurum and M. smegmatis the reserpine effect was abolished by the addition of glucose. These data suggest that rifampicin may be removed from wild-type mycobacteria by efflux, but that the pump(s) is expressed at low level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10660497     DOI: 10.1093/jac/45.2.159

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  36 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 3.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

4.  Differential expression of sigH paralogs during growth and under different stress conditions in Mycobacterium smegmatis.

Authors:  Anirudh K Singh; Bhupendra N Singh
Journal:  J Bacteriol       Date:  2009-02-13       Impact factor: 3.490

Review 5.  Peptidoglycan in Mycobacteria: chemistry, biology and intervention.

Authors:  Tripti Raghavendra; Saniya Patil; Raju Mukherjee
Journal:  Glycoconj J       Date:  2018-09-19       Impact factor: 2.916

6.  AccD6, a key carboxyltransferase essential for mycolic acid synthesis in Mycobacterium tuberculosis, is dispensable in a nonpathogenic strain.

Authors:  Jakub Pawelczyk; Anna Brzostek; Laurent Kremer; Bozena Dziadek; Anna Rumijowska-Galewicz; Marta Fiolka; Jaroslaw Dziadek
Journal:  J Bacteriol       Date:  2011-10-07       Impact factor: 3.490

7.  Identification and Characterization of Mycobacterial Species Using Whole-Genome Sequences.

Authors:  Marco A Riojas; Andrew M Frank; Samuel R Greenfield; Stephen P King; Conor J Meehan; Michael Strong; Alice R Wattam; Manzour Hernando Hazbón
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Energy metabolism and drug efflux in Mycobacterium tuberculosis.

Authors:  Philippa A Black; Robin M Warren; Gail E Louw; Paul D van Helden; Thomas C Victor; Bavesh D Kana
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

9.  Mycobacterium tuberculosis is able to accumulate and utilize cholesterol.

Authors:  Anna Brzostek; Jakub Pawelczyk; Anna Rumijowska-Galewicz; Bozena Dziadek; Jaroslaw Dziadek
Journal:  J Bacteriol       Date:  2009-08-28       Impact factor: 3.490

10.  Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis.

Authors:  Jansy Sarathy; Véronique Dartois; Thomas Dick; Martin Gengenbacher
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.